Floatz logo

Huazhi Rougan Granule

Huazhi Rougan Granule

Nanjing First Hospital, Nanjing Medical UniversityN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Huazhi Rougan Granule cohort.

Asset / SponsorPhaseRating
Pioglitazone
Yonsei University
Phase 4BBB
Metformin
Taipei City Hospital
Phase 4BBB
Empagliflozin
Military University Hospital, Prague
Phase 4BB
Glibenclamide
Takeda
Phase 4BB
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one
Tanta University
Phase 4BB

View all 50 →

Same molecule, other indications

Huazhi Rougan Granule is also rated in:

Efficacy and SafetyDormant
BB
Indicative ·
68 / 100
View asset →
Helicobacter pylori infection, susceptibility toDormant
D
Indicative ·
30 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →